Zydus, A Leading Discovery-Based Global Pharmaceutical Company, Has Received Permission To Initiate The Phase Ii (A) Clinical Study Of Its Nlrp3 Inhibitor "Zyil1" In Patients With Cryopyrin-Associated Periodic Syndrome (Caps) In Australia. Phase Ii (A) Clinical Trial In Australia Will Study The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics In Patients With Cryopyrin Associated Periodic Syndrome (Caps). Cryopyrin-Associated Periodic Syndrome (Caps) Is Caused By Nlrp3 Activating Mutations That Cause Activation Of The Cryopyrin Inflammasome And Release Of Inflammatory Cytokines Including Il-1
